Boston Scientific (BSX)
(Delayed Data from NYSE)
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Align Technology Stock Dips on Macroeconomic Issues, FX Headwind
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.
COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD
by Zacks Equity Research
Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
by Zacks Equity Research
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
by Zacks Equity Research
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Reasons to Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
RVTY's strong product portfolio raises optimism about the stock.
Boston Scientific (BSX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Boston Scientific (BSX) closed at $81.37, marking a -0.72% move from the previous day.
QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping
by Zacks Equity Research
QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.
Should You Continue to Retain ABT Stock in Your Portfolio Now?
by Zacks Equity Research
Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.
Butterfly Network's Stock Surges on iQ3 Device Launch in Europe
by Zacks Equity Research
Shares of BFLY gain almost 27% following the announcement of the launch of its latest handheld ultrasound device, Butterfly iQ3, in Europe.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
by Zacks Equity Research
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Reasons to Retain STERIS Stock in Your Portfolio for Now
by Zacks Equity Research
STE's strong prospects in the healthcare business arm bode well for investors.
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
by Zacks Equity Research
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
Reasons to Retain Cardinal Health Stock in Your Portfolio Now
by Zacks Equity Research
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump
by Zacks Equity Research
EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Should You Continue to Retain PODD Stock in Your Portfolio Now?
by Zacks Equity Research
Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's strong product portfolio raises optimism about the stock.
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock
by Zacks Equity Research
Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
by Zacks Equity Research
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
Dorsata's Alliance on Adnexal Masses to Support Aspira Stock
by Zacks Equity Research
AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.
Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock
by Zacks Equity Research
IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.
Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Boston Scientific (BSX) closed at $81.79, indicating a +1.39% shift from the previous trading day.
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
by Zacks Equity Research
CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
by Zacks Equity Research
BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
by Zacks Equity Research
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.